OBJECTIVE: The objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months. PATIENTS AND METHODS: Twenty-three consecutive patients presented with bone metastases and underwent therapy with zoledronic acid from December 2004. All patients underwent CT of the chest, abdomen, and pelvis. Bone density, measured in Hounsfield units (HU), was determined by segmenting lesions in the same anatomical area of the metastasis sites on the axial images of the sequential series of CT examinations. The effects of zoledronic acid were evaluated by calculating absolute and relative increases in bone density. RESULTS: The patients presented with multiple metastases in 65% of the cases. When compared with the baseline, all groups demonstrated a significant increase in bone density, which significantly (p < 0.01) correlated with the number of zoledronic acid administrations. There was increased bone density of at least 100% in 57%, and an increase of at least 50% in 87% of the patients. This increase was significant in both lytic and sclerotic metastases after 3 months of therapy. No significant bone density difference was found in normal-appearing bone. CONCLUSION: Bone density measured by CT increases at metastatic sites after zoledronic acid treatment, regardless of the type of metastasis, in contrast to apparently normal bone.
OBJECTIVE: The objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months. PATIENTS AND METHODS: Twenty-three consecutive patients presented with bone metastases and underwent therapy with zoledronic acid from December 2004. All patients underwent CT of the chest, abdomen, and pelvis. Bone density, measured in Hounsfield units (HU), was determined by segmenting lesions in the same anatomical area of the metastasis sites on the axial images of the sequential series of CT examinations. The effects of zoledronic acid were evaluated by calculating absolute and relative increases in bone density. RESULTS: The patients presented with multiple metastases in 65% of the cases. When compared with the baseline, all groups demonstrated a significant increase in bone density, which significantly (p < 0.01) correlated with the number of zoledronic acid administrations. There was increased bone density of at least 100% in 57%, and an increase of at least 50% in 87% of the patients. This increase was significant in both lytic and sclerotic metastases after 3 months of therapy. No significant bone density difference was found in normal-appearing bone. CONCLUSION: Bone density measured by CT increases at metastatic sites after zoledronic acid treatment, regardless of the type of metastasis, in contrast to apparently normal bone.
Authors: Amna Ibrahim; Nancy Scher; Grant Williams; Rajeshwari Sridhara; Ning Li; Gang Chen; John Leighton; Brian Booth; Jogarao V S Gobburu; Atiqur Rahman; Yung Hsieh; Rebecca Wood; Debra Vause; Richard Pazdur Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: Edward Chow; Lori Holden; Joel Rubenstein; Monique Christakis; Katharina Sixel; Marjan Vidmar; Joel Finkelstein; Charles Hayter; Andrew Loblaw; Rebecca Wong; Ewa Szumacher; Cyril Danjoux Journal: Radiother Oncol Date: 2004-03 Impact factor: 6.280
Authors: C C Quattrocchi; S Piciucchi; M Sammarra; D Santini; B Vincenzi; G Tonini; R F Grasso; B B Zobel Journal: Radiol Med Date: 2007-10-21 Impact factor: 6.313
Authors: F D'Agostino; P Dell'Aia; C C Quattrocchi; R Del Vescovo; R Setola; R F Grasso; B Beomonte Zobel Journal: Radiol Med Date: 2010-06-24 Impact factor: 3.469
Authors: Joerg Stattaus; Steffen Hahn; Thomas Gauler; Wilfried Eberhardt; Stefan P Mueller; Michael Forsting; Susanne C Ladd Journal: Eur Radiol Date: 2008-08-02 Impact factor: 5.315
Authors: S Gourtsoyianni; S Hwang; D M Panicek; J Zheng; C Moskowitz; H Scher; M Morris; H Hricak Journal: Br J Radiol Date: 2012-09 Impact factor: 3.039